Picture of Nyxoah SA logo

NYXH — Nyxoah SA News Story

0.000.00%
be flag iconLast trade - 00:00
HealthcareHighly SpeculativeSmall CapSucker Stock

Nyxoah Q2 revenue surges on U.S. growth, but margins drop

Nyxoah Q2 revenue surges on U.S. growth, but margins drop


Overview

  • Belgium medical device maker's Q2 revenue rose sharply yr/yr on U.S. commercialization

  • Gross margin for Q2 declined to 60% from 63% due to higher U.S. revenue mix

  • Company maintained full-year revenue and margin outlook, raised operating expense guidance


Outlook

  • Nyxoah expects 2026 worldwide net revenue of €36 mln to €40 mln

  • Company sees 2026 gross margin in the range of 60% to 62%

  • Nyxoah now expects 2026 total operating expenses of €99 mln to €102 mln


Result Drivers

  • U.S. COMMERCIALIZATION - Co said revenue growth was driven by expansion of U.S. commercialization activities following FDA approval

  • SALES FORCE AND ACCOUNT ACTIVATION - Co cited increased number of active sales reps, new surgeon training, and doubling of active accounts as supporting launch momentum

  • REIMBURSEMENT ENVIRONMENT - Co said 100% approval rate on prior authorization submissions and clarity on coding supported accelerating U.S. revenue growth


Company press release: ID:nGNE2CHRHm


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Loss Per Share

EUR 0.58

Q2 Gross Margin

60.00%

Q2 Gross Profit

EUR 4.58 mln

Q2 Loss Per Basic Share

EUR 0.58


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

  • Wall Street's median 12-month price target for Nyxoah SA is €5.30, about 323.3% above its August 5 closing price of €1.25


Reuters Recommended Reads

  • Aug 3 - Inspire Medical Q2 revenue falls less than expected

  • Aug 5 - UK's LivaNova Q2 revenue beats estimates; lifts 2026 outlook

  • Aug 5 - Insulet Q2 revenue beats on higher Omnipod sales


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Nyxoah SA

See all news